Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

648
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
648
Drug Therapy01:28

Drug Therapy

364
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
364
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.1K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic utility of quantitative susceptibility mapping in Parkinson's disease and atypical parkinsonism: A systematic review and meta-analysis.

NeuroImage·2026
Same author

An intelligent closed-loop CES for depression treatment using brain signals and machine learning.

MethodsX·2025
Same author

Abnormalities of brain imaging in COVID-19 patients with neurological symptoms.

Current journal of neurology·2023
Same author

Baseline executive functions and receiving cognitive rehabilitation can predict treatment response in people with opioid use disorder.

Journal of substance abuse treatment·2021
Same author

The Cognitive Model of Negative Symptoms in Schizophrenia: A Hierarchical Component Model With PLS-SEM.

Frontiers in psychiatry·2021
Same author

Prognostic Factors Associated with Survival in Patients Infected with COVID-19: A Retrospective Study on 214 Patients from Iran.

Archives of Iranian medicine·2021

Related Experiment Video

Updated: Mar 12, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

10.3K

Methamphetamine-Associated Psychosis and Treatment With Haloperidol and Risperidone: A Pilot Study.

Mercede Samiei1, Mohammad Vahidi1, Omid Rezaee1

  • 1Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, IR Iran.

Iranian Journal of Psychiatry and Behavioral Sciences
|November 9, 2016
PubMed
Summary
This summary is machine-generated.

Haloperidol and Risperidone effectively treat methamphetamine-associated psychosis positive symptoms. This pilot study found no significant difference in effectiveness between these two antipsychotic medications for methamphetamine-dependent patients.

Keywords:
HaloperidolMethamphetaminePsychosisRisperidoneTreatment

More Related Videos

Operant Procedures for Assessing Behavioral Flexibility in Rats
08:30

Operant Procedures for Assessing Behavioral Flexibility in Rats

Published on: February 15, 2015

21.7K
Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
06:25

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

9.1K

Related Experiment Videos

Last Updated: Mar 12, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

10.3K
Operant Procedures for Assessing Behavioral Flexibility in Rats
08:30

Operant Procedures for Assessing Behavioral Flexibility in Rats

Published on: February 15, 2015

21.7K
Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
06:25

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

9.1K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Neuroscience

Background:

  • First-generation antipsychotics may be more effective for psychotic symptoms than second-generation ones.
  • Limited research exists on comparing specific antipsychotics for methamphetamine-associated psychosis (MAP).

Purpose of the Study:

  • This pilot study aimed to compare the effectiveness of Haloperidol and Risperidone in treating positive symptoms of psychosis in methamphetamine-dependent patients.
  • It was the first study of its kind conducted in Iran.

Main Methods:

  • A randomized clinical trial involving 44 methamphetamine-dependent patients diagnosed with MAP.
  • Patients were randomly assigned to receive either Haloperidol (5-20 mg) or Risperidone (2-8 mg).
  • Assessments using the Scale for the Assessment of Positive Symptoms (SAPS) were conducted at baseline, weekly during treatment, and at follow-up.

Main Results:

  • Both Haloperidol and Risperidone demonstrated significant effectiveness (< 0.05) in treating positive symptoms of MAP.
  • No significant difference in effectiveness was observed between Haloperidol and Risperidone.
  • Treatment effects for both medications improved within the first two weeks and remained stable thereafter.

Conclusions:

  • Haloperidol and Risperidone are both effective treatments for the positive symptoms of methamphetamine-associated psychosis.
  • Further research is recommended to investigate long-term effects and compare efficacy in larger patient populations.